Epitalon (epithalon): benefits, side effects and what the research shows

Epitalon, also spelled epithalon, is the tetrapeptide alanine-glutamic acid-aspartic acid-glycine (AEDG). According to a 2025 review, it was synthesised based on the amino acid composition of epithalamin, a polypeptide extract of cattle pineal gland, before it was later reported to be present in that extract ^[1]. Most research on it comes from V. Kh. Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology and collaborators.

It is important to distinguish epitalon from epithalamin. Epithalamin is the crude extract; epitalon is a single defined synthetic peptide. Some human studies quoted in connection with epitalon, such as a 2003 longevity report, actually used epithalamin ^[6].

In 2017 the same group reported detecting AEDG among the tetrapeptides of a pineal polypeptide complex using mass spectrometry, and argued that the effects of the extract are determined by this component ^[18]. That argument comes from the developers and has not been tested independently.

Epitalon is often discussed with other peptides marketed for longevity or sleep, such as DSIP and MOTS-c. For background on how such products are sold, see what research peptides are.

There is no difference between epitalon and epithalon. Both names, and a third spelling, epitalone, refer to the same tetrapeptide, Ala-Glu-Asp-Gly ^[1]. Scientific papers use all three, sometimes alongside the one-letter code AEDG, and some early papers used the trade-mark form Epitalon® ^[12]. The epithalon peptide sold online is, if correctly made, the same molecule as the epitalon peptide; what differs between vials is purity and content, not the name.

Epithalamin, by contrast, is a different product: an extract of cattle pineal glands that contains a mixture of free amino acids and short peptides ^[18]. Mixing up the two names is the most common source of confusion in claims about human benefits, because several human studies used the extract ^[6].

Some sellers also offer “N-acetyl epitalon amidate”, a chemically modified version with capped ends. We found no published study of this modified form in PubMed, so nothing is known about whether it behaves like epitalon in the body.

The best-known claim is that epitalon activates telomerase, the enzyme that maintains telomeres at the ends of chromosomes. In a brief 2003 report, adding epitalon to cultures of human fetal fibroblasts, which normally lack telomerase activity, induced expression of the enzyme’s catalytic subunit, telomerase activity and telomere lengthening ^[2]. An independent 2025 study from Brunel University London found dose-dependent telomere lengthening in normal human cells through increased hTERT and telomerase activity; in two breast cancer cell lines, telomeres also lengthened, but through a different mechanism called alternative lengthening of telomeres (ALT) ^[3].

Epitalon is also described as a pineal regulator that influences melatonin. This is not consistent across studies: a 2003 experiment in isolated pineal glands from young and old rats found no significant effect of the tetrapeptide on melatonin secretion at any concentration tested ^[5].

The mechanism of action is not settled. The 2025 review lists effects on melatonin synthesis, interleukin-2 gene activity, thymus cells and several enzymes, including telomerase, and concludes that it remains uncertain whether these are its only mechanisms ^[1]. The developers have proposed that short peptides of this family enter cells and bind to histone proteins or nucleic acids to change gene activity, an idea set out, for example, for the related peptide pinealon ^[16]. The evidence for this comes mainly from their own laboratory and computer-modelling work ^[1].

Telomerase rebuilds the protective telomere caps on chromosome ends, but many human cell types, such as the fibroblasts used in the 2003 study, normally show little or no telomerase activity ^[2]. That is why a peptide said to switch telomerase on attracts attention. The evidence for epitalon doing this comes from three kinds of study, all outside the human body.

First, cultured human cells: the 2003 fibroblast report ^[2] and the 2025 Brunel study, which is the only independent laboratory confirmation we found and which also showed the effect in breast cancer cells ^[3]. Second, other cell systems: a 2025 study in cattle eggs and embryos reported that epitalon raised telomerase activity and improved egg maturation and embryo development in the laboratory ^[19]. Third, animal work on ageing markers and lifespan, described below ^[4]. A related 2022 study by researchers outside the developers’ group found that epitalon added to culture medium reduced reactive oxygen species and damage in mouse eggs ageing after ovulation, and linked this to effects on mitochondria rather than telomeres ^[24].

What is missing is any measurement of telomere length or telomerase activity in people given epitalon. We found no human study that measured either. So the claim that epitalon lengthens human telomeres is an extrapolation from cell cultures, and whether longer telomeres in a dish would translate into slower ageing, or into higher cancer risk, in a person is unknown.

In a lifespan study in female SHR mice, animals received epitalon (1.0 µg per mouse, about 30–40 µg/kg) by injection under the skin on five consecutive days each month from three months of age until death. Epitalon did not change mean lifespan, food intake or body weight. It increased the lifespan of the longest-lived 10% of mice by 13.3% and maximum lifespan by 12.3%, reduced chromosome aberrations in bone marrow cells, and did not change total tumour incidence, although leukaemia was less frequent ^[4]. This was a single study of 54 mice per group from the developing group.

Other laboratory work from the same group reports effects on gene expression, chromatin and cell differentiation, which are summarised in the 2025 review ^[1]. Independent replication of the main findings is limited.

Antioxidant effects are another common claim. A 2025 study, with Khavinson among the authors, found that epitalon restored delayed wound healing in human retinal cells exposed to high glucose, reduced markers of scarring and was described by the authors as acting as an antioxidant ^[17]. This was a cell-culture model of diabetic eye disease, not a treatment study.

Claims about skin and hair rest on very little. A 2016 study from the same group reported that AEDG and related short peptides reduced an enzyme linked to tissue breakdown and increased markers of cell renewal in ageing skin fibroblasts in culture ^[21]. We found no human study of epitalon for skin, hair growth or muscle, and nothing to support its use in bodybuilding.

Sleep is one of the main reasons people search for epitalon, and it was the use considered by the FDA’s advisory committee in 2026 ^[9]. The supporting data are indirect. In a 2001 study of female rhesus monkeys, the developers reported that epitalon significantly stimulated evening melatonin production in older animals and normalised the daily rhythm of cortisol ^[11]. The abstract gives no numbers of animals or doses.

The closest thing to human data is a 2020 Russian-language paper from the developers’ network, which reported that AEDG raised urinary excretion of a melatonin breakdown product (6-sulfatoxymelatonin) 1.7-fold in middle-aged people whose levels were low to begin with, and altered the activity of circadian “clock” genes in their blood cells ^[23]. The abstract does not describe the number of participants, the route, the dose or whether there was a control group, and the study did not measure sleep.

Against that, the 2003 study of isolated rat pineal glands found no effect of epitalon on melatonin secretion at any concentration ^[5]. We found no controlled trial measuring sleep in people given epitalon. Claims about deeper sleep or better sleep quality are therefore not supported by published human data.

We found no large randomised controlled trial of synthetic epitalon. A 2002 report from Khavinson’s group described epitalon treatment in patients with degenerative retinal disease and stated a positive clinical effect in 90% of cases, but the abstract gives little detail on design, numbers or controls ^[7].

The most widely quoted human “longevity” data concern the extract, not epitalon. In a 2003 report, 266 older people were followed for six to eight years after courses of thymalin (a thymus extract) and/or epithalamin; the authors reported lower mortality in treated groups, including a 1.6–1.8-fold reduction with epithalamin ^[6]. This was not a trial of epitalon, the allocation and blinding methods are not described in the abstract, and the findings have not been independently reproduced.

There are no epitalon human clinical trials registered on ClinicalTrials.gov: a search for “epitalon” and “epithalon” in September 2026 returned no studies ^[20]. That does not rule out unregistered studies, but it means there is no registered trial whose methods and results can be checked.

There is no human evidence on which to base an answer. The animal studies gave epitalon in short monthly courses for most of the animals’ lives and measured lifespan or tumours at death ^{[4] [12]}. Cell studies measured telomere changes over days to weeks of culture ^{[2] [3]}. None of these timepoints tells you when, or whether, a person would notice an effect, and before-and-after accounts online are not controlled.

The published animal studies gave epitalon by injection under the skin ^{[4] [12] [13]}. Epitalon is also sold as an epitalon nasal spray, as sublingual drops and as capsules or tablets. We found no published study measuring how much epitalon reaches the blood by any of these routes, and no study of its oral bioavailability.

Quality is a separate concern. A 2015 study in Drug Testing and Analysis identified epitalon in two illegal pharmaceutical preparations ^[14], which shows that it circulates in unregulated products whose content is not checked.

In the mouse lifespan study, epitalon was given at 1.0 µg per mouse (about 30–40 µg/kg) subcutaneously on five consecutive days each month ^[4]. Cell studies used a range of concentrations in culture ^{[2] [3]}. No human dose of epitalon has been established by a controlled trial, animal doses should not be converted to human doses, and nothing here is a recommendation. The peptide calculator converts vial contents to concentrations only.

Other animal studies used similar small amounts. In HER-2/neu transgenic mice, epitalon was given at 1 µg per mouse under the skin for five consecutive days every month ^[12]. In older female C3H/He mice, it was injected at 0.1 µg five times a week for six and a half months ^[13]. The monkey melatonin study abstract does not state a dose ^[11].

Vial arithmetic is the same for any peptide. A 10 mg vial made up with 1 mL of liquid gives 10 mg/mL; with 2 mL it gives 5 mg/mL. On a U-100 insulin syringe one unit is 0.01 mL, so at 5 mg/mL one unit contains 0.05 mg. These are calculations, not doses. The cycles and dosing charts shared online do not come from published human trials. See our guide to bacteriostatic water for what the diluent is.

The mouse lifespan study reported no effect on food intake or body weight and described long-term administration as safe in mice ^[4]. There are no adequate human safety data. Because epitalon is claimed to switch on telomerase, and cancer cells commonly rely on telomere maintenance, the 2025 finding that it lengthened telomeres in breast cancer cell lines is relevant to any safety assessment, though its significance for people is unknown ^[3].

The FDA has said that compounded drugs containing epitalon may pose a risk of immune reactions (immunogenicity) for some routes of administration and of peptide-related impurities ^[8].

No human study has recorded side effects of epitalon in a way that can be checked, so lists of side effects on sales pages are not based on trial data. The main practical risks are those of any unregulated injectable: wrong content, impurities and contamination. Independent third-party testing reduces, but does not remove, those risks.

Worry about epitalon and cancer follows from the telomerase claim, because cancer cells commonly rely on maintaining their telomeres, as noted above. The developers’ animal studies point the other way. In HER-2/neu transgenic mice, which develop breast tumours, monthly epitalon reduced the total number and maximum size of tumours and the size of lung metastases, and lowered HER-2/neu gene activity in the tumours ^[12]. In older C3H/He mice, epitalon reduced the number of animals with malignant tumours, and no metastases were found in treated mice compared with 3 of 9 tumour-bearing controls ^[13]. In SHR mice, total tumour incidence did not change ^[4].

These studies are small, come mostly from the same research network, and use mouse strains with specific tumour patterns. The only independent cell study found that epitalon lengthened telomeres in breast cancer cells ^[3]. Taken together, there is no human evidence either that epitalon causes cancer or that it prevents it.

Pinealon is another short synthetic peptide from Khavinson’s group. It is a tripeptide, Glu-Asp-Arg (EDR), whereas epitalon is the tetrapeptide Ala-Glu-Asp-Gly ^{[15] [1]}. Despite the similar name, pinealon is studied mainly for the brain rather than the pineal gland. In cell studies it limited the build-up of reactive oxygen species and reduced cell death under oxidative stress ^[15], and a 2020 review by its developers describes neuroprotective effects in cell and animal models and reports improved memory in older patients, citing the group’s own earlier work ^[16].

No study we found has compared pinealon with epitalon, or tested them together. Pages that recommend combining them, or combining DSIP with epitalon for sleep, are not drawing on published combination data. Both peptides share the same evidence problem: almost all of the work comes from one research network, and neither has a registered human trial.

Epitalon is not approved as a medicine anywhere we are aware of. In the US, the FDA previously placed it in category 2 of its interim compounding policy, the list of bulk substances that may present significant safety risks; the nomination was later withdrawn and the FDA now lists it among substances previously in category 2 ^[8].

On 24 July 2026 the FDA’s Pharmacy Compounding Advisory Committee considered epitalon for insomnia ^[9]. The FDA’s meeting page posted no votes or outcome, the committee’s advice is not binding, and as of September 2026 the FDA has not acted ^[9]. We have not confirmed its status on the WADA Prohibited List. See our legal status overview and the UK page.

In Canada, a Health Canada advisory of April 2026 names epitalon among peptides it has seized as unauthorised products and says research-use-only labelling does not make them legal ^[22]. See peptide rules in Canada.

We found no published study of epitalon’s half-life in people or its blood levels after a dose, so there is no established figure.

Epitalon is sold as a freeze-dried powder. Peptides are generally stored cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. See how to store peptides.

Compare prices, read how to read a COA, and check for third-party tested suppliers.

You can also compare epitalon UK prices and epitalon suppliers in Australia. Being listed on PepFinder does not mean a product is legal to buy for human use where you live. Our guide on how to spot a fake peptide supplier lists warning signs to check before buying.